# US 2015/0104801 A1 · Methods and compositions for exosome isolation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104801 A1
- Document ID: US20150104801A1
- Status: Published application
- Kind: A1
- Application number: 14/523,764
- Filed: 2014-10-24
- Published: 2015-04-16
- Earliest claimed: 2012-04-17
- Assignees: Life Technologies Corporation
- Applicants: Life Technologies Corporation
- Inventors: Alexander VLASSOV; Mu LI; Emily ZERINGER; Richard CONRAD
- Web page: https://patentgrep.com/patent/US20150104801A1

## CPC

- G01N 1/34: Purifying; Cleaning {(processes or apparatus for extracting or separating nucleic acids from biological samples C12N15/1003)}
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- G01N 33/5005: {involving human or animal cells (immunoassay G01N33/56966; immunoassays of protozoa G01N33/56905; protozoa in screening assays C12Q1/025)}
- G01N 33/5076: {involving cell organelles, e.g. Golgi complex, endoplasmic reticulum}
- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Disclosed are methods, compositions and kits for the isolation of exosomes from biological fluids and tissues. Volume-excluding polymers are used to precipitate exosomes from biological samples thereby allowing exosome isolation by low-speed (benchtop) centrifugation or filtration. Further fractionation of exosomes after precipitation is also described.

## Claims

### Claim 1

A method for the isolation of exosomes from a biological fluid sample comprising:
a) adding a volume-excluding polymer to the biological fluid sample,
b) incubating the biological fluid sample with the volume-excluding polymer; and
c) isolating the precipitated exosomes from the biological fluid sample.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The method of claim 1, wherein the molecular weight of the volume-excluding polymer is from 3000 to 10000 daltons.

### Claim at position 4

4-5. (canceled)

### Claim 6 (depends on 1)

The method of claim 1, wherein the concentration of volume-excluding polymer upon mixing with the biological fluid is from 3% to 15%.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The method of claim 1, further comprising the step of clarifying the biological fluid sample before adding the volume-excluding polymer.

### Claim 9 (depends on 1)

The method of claim 1 further comprising the step of isolating nucleic acid and protein from the exosomes.

### Claim at position 9

10-12. (canceled)

### Claim 13 (depends on 1)

The method of claim 1, further comprising fractionating the isolated exosomes.

### Claim 14 (depends on 1)

The method of claim 1, wherein the volume-excluding polymer is polyethylene glycol, dextran, dextran sulfate, dextran acetate, polyvinyl alcohol, polyvinyl acetate, or polyvinyl sulfate.

### Claim 15

(canceled)

### Claim 16 (depends on 1)

The method of claim 1, further comprising contacting the biological fluid sample prior to the addition of the volume-excluding polymer with a protease, under conditions suitable for digestion of protein.

### Claim 17 (depends on 16)

The method of claim 16, wherein the protease is proteinase K.

### Claim 18

A method for the isolation of exosomes from a biological tissue sample comprising:
a) lysing the biological tissue sample,
b) clarifying the lysed sample
c) adding a volume-excluding polymer to the clarified sample,
d) incubating the clarified sample with the volume-excluding polymer, and
e) isolating the precipitated exosomes.

### Claim 19

(canceled)

### Claim 20 (depends on 18)

The method of claim 18, wherein the molecular weight of the volume-excluding polymer is from 3000 to 10000 daltons.

### Claim at position 18

21-22. (canceled)

### Claim 23 (depends on 18)

The method of claim 18, wherein the concentration of volume-excluding polymer upon mixing with the biological sample is from 3% to 15%.

### Claim 24

(canceled)

### Claim 25 (depends on 18)

The method of claim 18, wherein the volume-excluding polymer is polyethylene glycol, dextran, dextran sulfate, dextran acetate, polyvinyl alcohol, polyvinyl acetate, or polyvinyl sulfate.

### Claim 26

(canceled)

### Claim 27 (depends on 18)

The method of claim 18 further comprising the step of isolating nucleic acid and protein from the exosomes.

### Claim at position 24

28-29. (canceled)

### Claim 30 (depends on 18)

The method of claim 18, further comprising contacting the biological tissue sample with a protease, under conditions suitable for digestion of protein, prior to the addition of the volume-excluding polymer.

### Claim 31

(canceled)

### Claim 32

A kit for the isolation of exosomes comprising:
a) one or more vessels containing one or more volume-excluding polymers, one or more buffers or one or more solutions for performing density gradient centrifugation of exosomes,
b) one or more vessels containing antibodies or other ligands which bind a surface marker exposed on the surface of the exosome, and
c) one or more solid supports which bind directly or indirectly to the exosomes.

### Claim 33 (depends on 32)

The kit of claim 32, wherein the volume-excluding polymer is selected from the group consisting of polyethylene glycol, dextran, dextran sulfate, dextran acetate, polyvinyl alcohol, polyvinyl acetate, or polyvinyl sulfate.

### Claim 34 (depends on 32)

The kit of claim 32, wherein the surface marker is selected from the group consisting of HLA DP haplotypes, HLA DQ haplotypes, HLA DR haplotypes, CD9, CD81, CD63 and CD82.

### Claim 35 (depends on 32)

The kit of claim 32, wherein the solid support is a magnetic particle.

### Claim 36 (depends on 32)

The kit of claim 32, further comprising a filtration device for separating exosomes by their size.
